beta
Trial Radar AI
One study matched filter criteria
Card View

CGM for Management of Type 2 Diabetes in Pregnancy (CGM2) 564

Recruiting
Clinical Trial NCT06628453 (CGM2) is an interventional study for Type 2 Diabetes Mellitus (T2DM), Pregnancy that is recruiting. It started on 8 April 2025 with plans to enroll 564 participants. Led by University of Alabama at Birmingham, it is expected to complete by 1 July 2029. The latest data from ClinicalTrials.gov was last updated on 15 June 2025.
Brief Summary

The goal of this clinical trial is to learn if continuous glucose monitoring works better than self-monitoring of blood glucose (fingersticks) to treat type 2 diabetes in pregnancy. It will also learn about all risk factors (biologic, personal, social) for maternal and infant complications in type 2 diabetes pregnancies. The main questions it aims to answer are:

  1. Does continuous glucose monitoring improve infant o...
Show More
Detailed Description
We will conduct a multicenter, open-label randomized controlled trial of pregnant individuals with T2DM to test the effectiveness of CGM at improving maternal and neonatal outcomes, compared to SMBG. All pregnant women who have T2DM will be screened for eligibility. If a patient is eligible, the study will be explained to them and if they consent to participate, they will be randomized centrally in a 1:1 ratio to CGM...Show More
Official Title

Continuous Glucose Monitoring for Management of Type 2 Diabetes in Pregnancy

Conditions
Type 2 Diabetes Mellitus (T2DM)Pregnancy
Publications
Scientific articles and research papers published about this clinical trial:
Other Study IDs
NCT ID Number
Start Date (Actual)
2025-04-08
Last Update Posted
2025-06-15
Completion Date (Estimated)
2029-07
Enrollment (Estimated)
564
Study Type
Interventional
PHASE
N/A
Status
Recruiting
Keywords
Diabetes
Pregnancy
CGM
Primary Purpose
Treatment
Design Allocation
Randomized
Interventional Model
Parallel
Masking
None (Open Label)
Arms / Interventions
Participant Group/ArmIntervention/Treatment
ExperimentalContinuous Glucose Monitoring
Real-time continuous glucose monitoring
CGM
Real-time continuous glucose monitoring
No InterventionSelf-Monitoring of Blood Glucose
Self-monitoring of blood glucose (standard of care)
N/A
Primary Outcome Measures
Outcome MeasureMeasure DescriptionTime Frame
Time in Range (TIR) at 34 weeks gestation
Percentage of time spent within target range (63-140mg/dL) on Continuous Glucose Monitoring at 34 weeks gestation
33 to 35 weeks gestation
Composite Neonatal Morbidity
Composite morbidity of the neonate including one or more of preterm birth (delivery less than 37 weeks for any indication), birth trauma (shoulder dystocia with nerve injury, clavicular or humeral fracture or 3 or more maneuvers to resolve), hypoglycemia (requiring treatment with dextrose gel or IV within 24 hours of birth), hyperbilirubinemia (requiring phototherapy within 72 hours of birth), large-for-gestational-age infant (birthweight greater than the 90th percentile for gestational age), and miscarriage, stillbirth or neonatal death prior to hospital discharge.
From the date of delivery to the date of neonatal hospital discharge, assessed up to 12 months of life
Secondary Outcome Measures
Outcome MeasureMeasure DescriptionTime Frame
Preterm birth
Delivery less than 37 weeks gestation
Delivery
Birth trauma
Shoulder dystocia with nerve injury, clavicular or humeral fracture or 3 or more maneuvers to relieve
Delivery
Neonatal hypoglycemia
Low neonatal glucose requiring treatment with dextrose gel or IV within 24 hours of life
Delivery to 24 hours of life
Hyperbilirubinemia
Elevated bilirubin requiring phototherapy within 72 hours of life
Delivery to 72 hours of life
Large-for-gestational-age (LGA) neonate
Birthweight greater than the 90th percentile for gestational age
Delivery
Small-for-gestational-age (SGA) neonate
Birthweight less than the 10th percentile for gestational age
Delivery
Fetal glucose
Concentration of umbilical cord blood glucose (mg/dL)
Delivery
Fetal insulin
Concentration of umbilical cord blood insulin (uU/mL)
Delivery
Fetal C-peptide
Concentration of umbilical cord blood C-peptide (ng/mL)
Delivery
Fetal leptin
Concentration of umbilical cord blood leptin (ng/mL)
Delivery
Fetal ghrelin
Concentration of umbilical cord blood ghrelin (uU/L)
Delivery
Fetal surfactant protein D
Concentration of umbilical cord blood surfactant protein D (ng/mL)
Delivery
Time Above Range (TAR) at 34 weeks
Percentage of time spent above range greater than 140mg/dL on Continuous Glucose Monitoring (CGM) at 34 weeks
33 to 35 weeks
Time Below Range (TBR) at 34 weeks
Percentage of time spent below range less than 63mg/dL on Continuous Glucose Monitoring at 34 weeks
33 to 35 weeks
Mean glucose at 34 weeks
Average glucose in mg/dL using Continuous Glucose Monitoring data at 34 weeks
33 to 35 weeks
Glucose Management Indicator (GMI)
Glucose management indicator as an estimate of hemoglobin A1c calculated using mean glucose on CGM at 34 weeks
33 to 35 weeks
Glucose variability at 34 weeks
Coefficient of variation calculated as the mean glucose divided by standard deviation using Continuous Glucose Monitoring data at 34 weeks
33 to 35 weeks
Mean fasting glucose at 34 weeks
Average glucose at 6-7am on Continuous Glucose Monitoring at 34 weeks
33 to 35 weeks
Hemoglobin A1c at Delivery
Hemoglobin A1c (%) at delivery
Delivery
Insulin total daily dose at delivery
Total number of units of insulin taken per day at time of delivery
Delivery
Cesarean delivery
First cesarean delivery or cesarean delivery after a history of prior cesarean
Delivery
Glucose Monitoring Satisfaction
Score on glucose monitoring satisfaction survey at delivery
Delivery
Fetal or neonatal death
Miscarriage (pregnancy loss less than 20 weeks), stillbirth (fetal death at 20 weeks or more), or neonatal death (death after birth up to 28 days of life)
From the date of randomization to the date of neonatal hospital discharge, assessed up to 12 months of life
Neonatal Intensive Care Unit (NICU) Admission
Admission to the neonatal intensive care unit with length of stay greater than 24 hours
From the date of delivery to the date of neonatal hospital discharge, assessed up to 12 months of life
Neonatal length of stay
Duration of neonatal hospitalization after delivery
From the date of delivery to the date of neonatal hospital discharge, assessed up to 12 months of life
Neonatal mechanical ventilation
Neonate requiring intubation and mechanical ventilation for respiratory support
From the date of delivery to the date of neonatal hospital discharge, assessed up to 12 months of life
Insulin increase during pregnancy
Percentage change in total daily dose of insulin at delivery compared to enrollment
From the date of randomization to the date of delivery, assessed up to 9 months
Preeclampsia
Elevated blood pressure greater than 140/90 mmHg after 20 weeks gestation with proteinuria or other severe features by ACOG criteria (may be superimposed on chronic hypertension or not)
From the date of randomization to the date of maternal hospital discharge after delivery, assessed up to 9 months
Postpartum infection
Developing one or more of endometritis, wound infection or other wound complication such as seroma, hematoma or dehiscence)
From the date of delivery through 6 weeks' postpartum
Glucose Monitoring Adherence
Defined as percentage of expected self-monitoring of blood glucose (SMBG) values completed based on recommended 4 values per day for participants in the SMBG arm and percentage of time Continuous Glucose Monitoring (CGM) in use in the CGM arm
From the date of randomization to the date of delivery, assessed up to 9 months
Participation Assistant
Eligibility Criteria

Eligible Ages
Adult
Minimum Age
18 Years
Eligible Sexes
Female
  • Type 2 diabetes mellitus treated with daily insulin injections or oral hypoglycemic agents diagnosed before pregnancy or at less than 14 weeks gestation with hemoglobin A1c 6.5% or greater
  • Pregnant with viable fetus at 6 to less than 23 weeks gestation
  • Maternal age 18-50 years old

  • Unable or unwilling to wear CGM due to intolerance to medical-grade adhesives or skin conditions
  • Multiple gestation
  • Major fetal anomaly or two or more minor fetal anomalies
  • Planned delivery outside study consortium
  • Participating in another conflicting interventional study
  • Participation in this trial in a previous pregnancy
  • Patient unable to consent
  • Physician refusal for other reasons
University of Alabama at Birmingham logoUniversity of Alabama at Birmingham478 active studies to explore
  • National Institutes of Health (NIH) logoNational Institutes of Health (NIH)
  • Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) logoEunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Study Responsible Party
Ashley N. Battarbee, Principal Investigator, Associate Professor, University of Alabama at Birmingham
Study Central Contact
Contact: Ashley Battarbee, MD, MSCR, 205-975-2361, [email protected]
7 Study Locations in 1 Countries

Alabama

University of Alabama at Birmingham, Birmingham, Alabama, 35233, United States
Ashley Battarbee, Contact, 205-975-2361, [email protected]
Recruiting

California

University of California at San Diego, San Diego, California, 92121, United States
Gladys Ramos, MD, Contact, 858-657-7200, [email protected]
Recruiting

North Carolina

University of North Carolina - Chapel Hill, Chapel Hill, North Carolina, 27599, United States
Kim Boggess, MD, Contact, 919-966-2131, [email protected]
Recruiting

Oregon

Oregon Health and Science University, Portland, Oregon, 97213, United States
Amy Valent, DO, MCR, Contact, 503-418-4200, [email protected]
Recruiting

Pennsylvania

University of Pennsylvania, Philadelphia, Pennsylvania, 19104, United States
Celeste Durnwald, MD, Contact, 800-789-7366, [email protected]
Recruiting

South Carolina

Prisma Health Greenville Memorial Hospital, Greenville, South Carolina, 29605, United States
Daniel Pasko, MD, Contact, 864-455-7000, [email protected]
Recruiting

Texas

University of Texas Health Science Center at Houston, Houston, Texas, 77030, United States
Michal Fishel Bartal, MD, Contact, 832-325-7133, [email protected]
Recruiting